Iloperidone in the treatment of schizophrenia: An evidence-based review of its place in therapy

Core Evidence

Volumn 11, Issue , 2016, Pages 49-61

  Tonin, Fernanda S ^a   Wiens, Astrid ^a   Fernandez Llimos, Fernando ^b   Pontarolo, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Clinical practice; Evidence based; Iloperidone; Schizophrenia

Indexed keywords

ILOPERIDONE; PROLACTIN;

AKATHISIA; ANGIONEUROTIC EDEMA; BRADYKINESIA; CLINICAL PRACTICE; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-5; DYSTONIA; ECG ABNORMALITY; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HEADACHE; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSOMNIA; META ANALYSIS; MULTICENTER STUDY (TOPIC); NAUSEA; NOSE OBSTRUCTION; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIAPISM; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROGRADE EJACULATION; REVIEW; RHINOPHARYNGITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDE; SYSTEMATIC REVIEW; TACHYCARDIA; TREMOR; XEROSTOMIA;

EID: 85015625406     PISSN: 15551741     EISSN: 1555175X     Source Type: Journal    
DOI: 10.2147/CE.S114094     Document Type: Review

References (74)

1. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012.
2. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.
3. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24(5):645-692.
4. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016; 388(10039):86-97.
5. Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: A systematic review and meta-Analysis. Ann Intern Med. 2012;157(7):498-511.
6. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50(11):884-897.
7. Tandon R. Schizophrenia and other psychotic disorders in DSM-5. Clin Schizophr Relat Psychoses. 2013;7(1):16-19.
8. Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150(1):3-10.
9. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;11:CD006633.
10. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: A meta-Analysis. Lancet. 2009;373(9657):31-41.
11. Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990 horizontal line 2013: A systematic literature review. BMC Psychiatry. 2015;15:193.
12. Ince P, Haddock G, Tai S. A systematic review of the implementation of recommended psychological interventions for schizophrenia: Rates, barriers, and improvement strategies. Psychol Psychother. 2016;89(3):324-350.
13. Laurens KR, Cullen AE. Toward earlier identification and preventative intervention in schizophrenia: Evidence from the London Child Health and Development Study. Soc Psychiatry Psychiatr Epidemiol. 2016;51(4):475-491.
14. Fusar-Poli P, Carpenter WT, Woods SW, McGlashan TH. Attenuated psychosis syndrome: Ready for DSM-5.1? Annu Rev Clin Psychol. 2014;10:155-192.
15. Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6): 764-771.
16. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry. 2004;161(3): 398-413.
17. Cioffi CL. Modulation of NMDA receptor function as a treatment for schizophrenia. Bioorg Med Chem Lett. 2013;23(18):5034-5044.
18. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996;3(5):241-253.
19. Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl- D-Aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69-108.
20. Landek-Salgado MA, Faust TE, Sawa A. Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry. 2016;21(1):10-28.
21. Sigmundsson T, Suckling J, Maier M, et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry. 2001;158(2):234-243.
22. Ellison-Wright I, Bullmore E. Meta-Analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res. 2009;108(1-3):3-10.
23. Olabi B, Ellison-Wright I, McIntosh AM, Wood SJ, Bullmore E, Lawrie SM. Are there progressive brain changes in schizophrenia? A meta-Analysis of structural magnetic resonance imaging studies. Biol Psychiatry. 2011;70(1):88-96.
24. Davis KL, Stewart DG, Friedman JI, et al. White matter changes in schizophrenia: Evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003;60(5):443-456.
25. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet. 2007;370(9584):319-328.
26. Roussos P, Haroutunian V. Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities. Front Cell Neurosci. 2014;8:5.
27. Hall J, Trent S, Thomas KL, O'Donovan MC, Owen MJ. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry. 2015;77(1):52-58.
28. Muller N, Myint AM, Schwarz MJ. Inflammation in schizophrenia. Adv Protein Chem Struct Biol. 2012;88:49-68.
29. Drexhage RC, Weigelt K, van Beveren, N, et al. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int Rev Neurobiol. 2011;101:169-201.
30. Bawa P, Pradeep P, Kumar P, Choonara YE, Modi G, Pillay V. Multitarget therapeutics for neuropsychiatric and neurodegenerative disorders. Drug Discov Today. Epub 2016 Aug 6.
31. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-Treatments meta-Analysis. Lancet. 2013;382(9896):951-962.
32. Winlow W, Profit L, Chrisp P. Aripiprazole: The evidence of its therapeutic impact in schizophrenia. Core Evid. 2006;1(4):251-264.
33. Kantrowitz J, Citrome L. Paliperidone: The evidence of its therapeutic value in schizophrenia. Core Evid. 2008;2(4):261-271.
34. Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: An update. Asian J Psychiatr. 2014;11:3-7.
35. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206-1227.
36. Tandon R. Antipsychotics in the treatment of schizophrenia: An overview. J Clin Psychiatry. 2011;72(suppl 1):4-8.
37. Keshavan MS, Lawler AN, Nasrallah HA, Tandon R. New drug developments in psychosis: challenges, opportunities and strategies. Prog Neurobiol. Epub 2016 Aug 9.
38. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-425.
39. Arif SA, Mitchell MM. Iloperidone: A new drug for the treatment of schizophrenia. Am J Health Syst Pharm. 2011;68(4):301-308.
40. Dopheide JA. Iloperidone: does it have a meaningful place in therapy? Am J Health Syst Pharm. 2011;68(4):297.
41. Corbett R, Griffiths L, Shipley JE, et al. Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev. 1997;3(2):120-147.
42. Orsolini L, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15(10):1329-1347.
43. Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010;6(12):1551-1564.
44. Mortimer AM. Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl. 2007;50:s7-s14.
45. Suzuki T, Uchida H, Sakurai H, et al. Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia. Psychiatry Res. 2015;227(2-3):265-269.
46. Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry. 2014;75(suppl 1):8-14.
47. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo-And ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(7 suppl 1):S20-S28.
48. Lavedan C, Volpi S, Polymeropoulos MH, Wolfgang CD. Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. Pharmacogenomics. 2008;9(3):289-301.
49. Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C - 759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res. 2010;175(3):271-273.
50. Volpi S, Heaton C, MacK K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009;14(11):1024-1031.
51. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(7 suppl 1):S4-S11.
52. Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short-Term treatment of schizophrenia: A post hoc analysis of pooled patient data from four phase III, placebo-And active-controlled trials. Hum Psychopharmacol. 2012;27(1):24-32.
53. Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33(1):3-10.
54. Weiden PJ, Manning R, Wolfgang CD, et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: The REPRIEVE study. CNS Drugs. 2016;30(8):735-747.
55. Citrome L, Weiden PJ, Alva G, et al. Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, openlabel, randomized clinical trial in 500 persons with schizophrenia. Clin Schizophr Relat Psychoses. 2015;8(4):183-195.
56. Weiden PJ, Citrome L, Alva G, et al. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res. 2014;153(1-3):160-168.
57. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long-Term safety and tolerability of iloperidone: Results from a 25-week, open-label extension trial. CNS Spectr. 2013;18(1):43-54.
58. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Longterm efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28(7 suppl 1):S29-S35.
59. Achalia R, Andrade C. Ventricular premature contractions associated with iloperidone. Indian J Psychiatry. 2013;55(2):195-196.
60. Dutta A, Barua S, Dan A, Chakraborty K, Mandal M. Iloperidoneinduced galactorrhea in a middle-Aged female. Indian J Psychol Med. 2012;34(4):396-398.
61. Muzyk AJ, Cvelich RG, Kincaid BR, Preud'homme XA. Angioedema occurring in patient prescribed iloperidone and haloperidol: A crosssensitivity reaction to antipsychotics from different chemical classes. J Neuropsychiatry Clin Neurosci. 2012;24(2):E40-E41.
62. Hwang YJ, Dixon SN, Reiss JP, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: A population-based cohort study. Ann Intern Med. 2014;161(4):242-248.
63. Tonin FS, Piazza T, Wiens A, Fernandez-Llimos F, Pontarolo R. Adverse events and treatment failure leading to discontinuation of recently approved antipsychotic drugs in schizophrenia: A network meta-Analysis. Schizophr Res. 2015;169(1-3):483-485.
64. Gohil K, Carramusa B. Schizophrenia therapy options increasing. P T. 2014;39(9):646-647.
65. Aldridge MA. Addressing non-Adherence to antipsychotic medication: A harm-reduction approach. J Psychiatr Ment Health Nurs. 2012;19(1):85-96.
66. Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: Theoretical background and practical recommendations. CNS Drugs. 2013;27(7):545-572.
67. Citrome L. A systematic review of meta-Analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012;13(11):1545-1573.
68. De Hert, M, Yu W, Detraux J, Sweers K, van Winkel, R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: A systematic review and exploratory meta-Analysis. CNS Drugs. 2012;26(9):733-759.
69. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568-575.
70. Das S, Saha I, Mondal S, Bandyopadhyay S. Nasal congestion with iloperidone therapy in a case series. J Young Pharm. 2013;5(3):108-109.
71. Freeman SA. Iloperidone-induced retrograde ejaculation. Int Clin Psychopharm. 2013;28(3):156.
72. Muzyk AJ, Cvelich RG, Kincaid BR, Preud'homme XA. Angioedema occurring in patient prescribed iloperidone and haloperidol:A crosssensitivity reaction to antipsychotics from different chemical classes. J Neuropsychiatry Clin Neurosci. 2012;24(2):E40-E41.
73. Ravani NN, Katke PH. Iloperidone-induced ejaculatory dysfunction: A case series. Indian J Psychiatry. 2016;58(1):87-89.
74. Rodriguez-Cabezas LA, Kong BY, Agarwal G. Priapism associated with iloperidone: A case report. Gen Hosp Psychiatry. 2014;36(4): 451.e455-451.e456.